Press Releases July 22, 2026 07:00 AM

Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026

Standard BioTools schedules Q2 2026 financial results release for August 5, 2026

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
LAB

Standard BioTools Inc., a life science tools company listed on NASDAQ under the ticker LAB, announced it will release its second quarter 2026 financial results after the U.S. market closes on August 5, 2026. The company specializes in providing standardized next-generation solutions to biomedical researchers to accelerate therapeutic development.

Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026
LAB
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Standard BioTools focuses on the life science tools industry, offering next-generation solutions for biomedical research.
  • The company's strategic consolidation and strong management aim to set new industry standards.
  • Q2 2026 financial results will be announced on August 5, 2026, after market close.

BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its second quarter 2026 financial results on Wednesday, August 5, 2026, after U.S. market close.

About Standard BioTools Inc.

Standard BioTools, Inc. (NASDAQ: LAB), is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world-class management team. The Company's established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster.

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply: standardbio.com/legal/terms-and-conditions/.
Patent and License Information: standardbio.com/legal/notices.

Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2026 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.

Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Investor Contact:
[email protected]


Risks

  • Financial results performance uncertainty that could impact stock price following release.
  • Industry competition in life science tools could affect future growth and profitability.
  • Regulatory and market conditions impacting biomedical research funding and demand.

More from Press Releases

Sachem Capital Reports Third Quarter 2026 Results Nov 16, 2026 Inter&Co Delivers Record 3Q26 Net Income of US$76.1 Million, With Strong Growth, Higher Margin and Better Efficiency Nov 12, 2026 Super League to Report Third Quarter 2026 Financial Results on Monday, November 16, 2026 Nov 12, 2026 UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights Nov 4, 2026 BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules Nov 4, 2026